ZEJULA and NUZYRA are not cheap products to make, and Zai Lab’s latest filing says the cost of producing and buying them stayed flat even as sales fell. That is the compact version of the problem: the commercial business got smaller, but several expenses did not get the memo.

Revenue for the three months ended March 31 fell to $99.6 million from $116.1 million a year earlier, a 14.2% decline. The operating loss widened to $69.4 million from $48.8 million, and cash fell to $651.3 million from $717.2 million.

The cost line is doing more work than the revenue line. Zai Lab’s operating margin deteriorated to negative 69.7% from negative 42.1%, because product costs held roughly steady against a smaller sales base while research and development expenses rose to $65.6 million from $47.9 million.

Management described the product-cost mix this way:

"Our cost of product revenue mainly consists of the costs of manufacturing ZEJULA and NUZYRA; costs of purchasing VYVGART / VYVGART Hytrulo, OPTUNE, QINLOCK, XACDURO, and AUGTYRO from our collaboration partners; any royalty fees incurred as a result of sales of our commercial products under our license and collaboration agreements; and amortization of capitalized post-approval milestone fees incurred under our license and 19 collaboration agreements."

Zai Lab, Form 10-Q, May 7, 2026.

In plain English, a meaningful part of the cost base is tied to products and partners, not just a factory that can be turned down with a switch. Zai Lab said product costs remained flat because lower sales were offset by a shift in product mix. Inventory rose to $86.0 million from $67.1 million as revenue declined.

The other side of the filing is investment in the pipeline. Research and development spending increased, with the company pointing to higher trial costs and licensing fees. The pre-clinical portion was especially active:

"Research and development expenses attributable to pre-clinical programs increased by $8.4 million, primarily driven by an increase in licensing fees for our license and collaboration agreements."

Zai Lab, Form 10-Q, May 7, 2026.

Net loss widened to $51.0 million from $36.0 million. Yet cash generation has a wrinkle: capital-spending intensity declined sharply, and free-cash-flow margin improved by 26.6 percentage points to negative 13.2%.

Cash still declined as investing and financing moved around the balance sheet. Investing used $22.3 million, compared with $326.1 million provided a year earlier, largely because short-term investment maturities contributed far less cash. Financing cash also fell, with $44.6 million more repayment of short-term bank borrowings partly offset by $10.6 million of new short-term debt proceeds.

The pipeline is not merely theoretical. In April, Zai Lab disclosed a global clinical-trial collaboration with Amgen to evaluate zoci with IMDELLTRA in small-cell lung cancer, alongside a separate collaboration with Boehringer Ingelheim. That supports the filing’s description of an active licensing and development machine, without resolving the near-term commercial slowdown.

The open loop is narrow but material: Zai Lab’s next quarterly report needs to put the 14.2% revenue decline, the inventory build, and the licensing-heavy R&D spending on the same timeline. Does inventory continue rising after the March 31 period’s revenue decline?